| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9009477 | Journal of the American Pharmacists Association | 2005 | 11 Pages |
Abstract
Compared with other statins, rosuvastatin offers the greatest lipid-lowering efficacy at the lowest dose in treating patients with dyslipidemia and with a similar safety profile over the short-term. Rosuvastatin may allow more patients to achieve their LDL-C goals than any other statin and at a lower dose than other agents.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Larry M. (Professor),